Horizon Pharma has acquired Raptor Pharmaceutical for $800 million. The transaction is expected to close in the fourth quarter of 2016. “The proposed acquisition of Raptor furthers our commitment to helping people with rare diseases and is a significant step in advancing our strategy to expand our rare disease business,” said Timothy Walbert, chairman, president and chief executive officer, Horizon Pharma. “Along with the potential for accelerated revenue growth, the additio...